NCT01646645: A reported trial by Memorial Sloan Kettering Cancer Center
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01646645 |
|---|---|
| Title | A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 13, 2012 |
| Completion date | Dec. 11, 2019 |
| Required reporting date | Dec. 10, 2020, midnight |
| Actual reporting date | Oct. 8, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |